Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor

American Journal of Transplantation

Volumn 6, Issue 5 I, 2006, Pages 1077-1083

  Yen, R D ^a   Bonatti, H ^a   Mendez, J ^a   Aranda Michel, J ^a   Satyanarayana, R ^a   Dickson, R C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adefovir; Hepatitis B immune globulin; Prophylaxis; YMDD mutation

Indexed keywords

ADEFOVIR DIPIVOXIL; CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; MUTANT PROTEIN; MYCOPHENOLIC ACID; TACROLIMUS; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN;

ADULT; ALCOHOL LIVER DISEASE; ALLOGRAFT; ANAMNESIS; ARTICLE; CASE REPORT; CONFUSION; GRAFT REJECTION; HEPATITIS B; HUMAN; HUMAN TISSUE; INFECTION RISK; LABORATORY TEST; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; ORGAN DONOR; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; SEROLOGY; SIDE EFFECT; STOMACH CARCINOMA; WEIGHT REDUCTION; ANTIBIOTIC RESISTANCE; BLOOD; DONOR; DRUG EFFECT; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; MIDDLE AGED;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MIDDLE AGED; TISSUE DONORS;

EID: 33745243283     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01313.x     Document Type: Article

References (41)

1. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-1674.
2. Bonatti H, Machicao V, Dickson RC, Mendez J. Results of liver transplantation in HBV core antibody positive individuals and recipients of allografts from HBV core antibody positive donors. Eur Surg 2005; 37: 15.
3. Roche B, Samuel D, Gigou M et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517-526.
4. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105-111.
5. Roque-Afonso AM, Feray C, Samuel D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-99.
6. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8: 556-561.
7. Chen YS, Wang CC, de Villa VH et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405-409.
8. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234.
9. Dodson SF, Issa S, Araya V et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-1584.
10. Uemoto S, Sugiyama K, Marusawa H et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-499.
11. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 51-58.
12. Nery JR, Nery-Avila C, Reddy KR et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 1179-1186.
13. Maguire D, Heaton ND, Smith HM. Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. Transplantation 2002; 73: 481-482.
14. Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003; 9: 1253-1257.
15. Jain A, Orloff M, Abt P et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplant Proc 2005; 37: 3187-3189.
16. Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant 2003; 3: 743-753.
17. Oon CJ, Chen WN, Lim N et al. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 1999; 41: 113-118.
18. Horlander JC, Boyle N, Manam R et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318: 304-307.
19. Ozaki T, Mochizuki H, Ichikawa Y, Fukuzawa Y, Yoshida S, Morimoto M. Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: A 3-year follow-up study. J Oral Sci 2000; 42: 147-150.
20. Rosen E, Rudensky B, Paz E et al. Ten-year follow-up study of hepatitis B virus infection and vaccination status in hospital employees. J Hosp Infect 1999; 41: 245-250.
21. Barnas GP, Hanacik LJ. Hepatitis B vaccine: Persistence of antibody following immunization. Infect Control Hosp Epidemiol 1988; 9: 147-150.
22. Bertoletti A, Southwood S, Chesnut R et al. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: Interaction with HLA and T-cell receptor. Hepatology 1997; 26: 1027-1034.
23. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995; 96: 1527-1534.
24. Shimada N, Yamamoto K, Kuroda MJ et al. HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol 2003; 23: 223-232.
25. Boni C, Penna A, Bertoletti A et al. Transient restoration of antiviral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.
26. Morita Y, Hosokawa M, Ebisawa M et al. Evaluation of cytomegalovirus- specific cytotoxic T-lymphocytes in patients with the HLA-A(*)02 or HLA-A(*)24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 803-811.
27. Macedo C, Donnenberg A, Popescu I et al. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl Immunol 2005; 14: 109-116.
28. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999; 117: 1386-1396.
29. Katsurada A, Marusawa H, Uemoto S, Kaburagi A, Tanaka K. Circulating antibody to hepatitis B core antigen does not always reflect the latent hepatitis B virus infection in the liver tissue (abstract). Gastroenterology 2002; 122: 219A.
30. Loss GE, Jr., Mason AL, Nair S et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003; 9: 1258-1264.
31. Fabrega E, Garcia-Suarez C, Guerra A et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transpl 2003; 9: 916-920.
32. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495.
33. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8: S82-S87.
34. Burton JR, Jr., Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: A survey of current practice in the United States. Liver Transpl 2003; 9: 837-842.
35. Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513-517.
36. Dodson SF. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin Transplant 2000; 14(Suppl. 2): 20-24.
37. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572-575; discussion 575-576.
38. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696.
39. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85.
40. de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: Recipient's risk. Transplantation 2003; 75: S49-S53.
41. Segovia R, Sanchez-Fueyo A, Rimola A et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 106-112.